{"pmid":32434416,"title":"Mice with humanized-lungs and immune system - an idealized model for COVID-19 and other respiratory illness.","text":["Mice with humanized-lungs and immune system - an idealized model for COVID-19 and other respiratory illness.","Lack of an appropriate animal model to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for COVID-19 pandemic disease, represents a significant hurdle in the process of understanding disease biology and evaluating therapeutic and preventive candidates. It is time for public health agencies to revisit regulation on transplantation of human pluripotent stem cells for the possibility of the development of a humanized mice model with a humanized lung.","Virulence","Pujhari, Sujit","Rasgon, Jason L","32434416"],"abstract":["Lack of an appropriate animal model to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for COVID-19 pandemic disease, represents a significant hurdle in the process of understanding disease biology and evaluating therapeutic and preventive candidates. It is time for public health agencies to revisit regulation on transplantation of human pluripotent stem cells for the possibility of the development of a humanized mice model with a humanized lung."],"journal":"Virulence","authors":["Pujhari, Sujit","Rasgon, Jason L"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434416","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/21505594.2020.1763637","keywords":["sars-cov-2","animal model","pluripotent stem cell","respiratory infectious diseases"],"topics":["Treatment"],"weight":1,"_version_":1667521393609146368,"score":9.490897,"similar":[{"pmid":32498696,"pmcid":"PMC7269898","title":"COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.","text":["COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.","Coronavirus disease 2019 (COVID-19) is a declared pandemic that is spreading all over the world at a dreadfully fast rate. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the pathogen of COVID-19, infects the human body using angiotensin-converting enzyme 2 (ACE2) as a receptor identical to the severe acute respiratory syndrome (SARS) pandemic that occurred in 2002-2003. SARS-CoV-2 has a higher binding affinity to human ACE2 than to that of other species. Animal models that mimic the human disease are highly essential to develop therapeutics and vaccines against COVID-19. Here, we review transgenic mice that express human ACE2 in the airway and other epithelia and have shown to develop a rapidly lethal infection after intranasal inoculation with SARS-CoV, the pathogen of SARS. This literature review aims to present the importance of utilizing the human ACE2 transgenic mouse model to better understand the pathogenesis of COVID-19 and develop both therapeutics and vaccines.","Hum Genomics","Lutz, Cathleen","Maher, Leigh","Lee, Charles","Kang, Wonyoung","32498696"],"abstract":["Coronavirus disease 2019 (COVID-19) is a declared pandemic that is spreading all over the world at a dreadfully fast rate. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the pathogen of COVID-19, infects the human body using angiotensin-converting enzyme 2 (ACE2) as a receptor identical to the severe acute respiratory syndrome (SARS) pandemic that occurred in 2002-2003. SARS-CoV-2 has a higher binding affinity to human ACE2 than to that of other species. Animal models that mimic the human disease are highly essential to develop therapeutics and vaccines against COVID-19. Here, we review transgenic mice that express human ACE2 in the airway and other epithelia and have shown to develop a rapidly lethal infection after intranasal inoculation with SARS-CoV, the pathogen of SARS. This literature review aims to present the importance of utilizing the human ACE2 transgenic mouse model to better understand the pathogenesis of COVID-19 and develop both therapeutics and vaccines."],"journal":"Hum Genomics","authors":["Lutz, Cathleen","Maher, Leigh","Lee, Charles","Kang, Wonyoung"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498696","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1186/s40246-020-00272-6","keywords":["angiotensin-converting enzyme 2 (ace2)","covid-19","coronavirus","sars-cov-2","transgenic mouse"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668890966360064001,"score":180.96231},{"pmid":32485164,"pmcid":"PMC7250783","title":"A Mouse Model of SARS-CoV-2 Infection and Pathogenesis.","text":["A Mouse Model of SARS-CoV-2 Infection and Pathogenesis.","Since December 2019, a novel coronavirus SARS-CoV-2 has emerged and rapidly spread throughout the world, resulting in a global public health emergency. The lack of vaccine and antivirals has brought an urgent need for an animal model. Human angiotensin-converting enzyme II (ACE2) has been identified as a functional receptor for SARS-CoV-2. In this study, we generated a mouse model expressing human ACE2 (hACE2) by using CRISPR/Cas9 knockin technology. In comparison with wild-type C57BL/6 mice, both young and aged hACE2 mice sustained high viral loads in lung, trachea, and brain upon intranasal infection. Although fatalities were not observed, interstitial pneumonia and elevated cytokines were seen in SARS-CoV-2 infected-aged hACE2 mice. Interestingly, intragastric inoculation of SARS-CoV-2 was seen to cause productive infection and lead to pulmonary pathological changes in hACE2 mice. Overall, this animal model described here provides a useful tool for studying SARS-CoV-2 transmission and pathogenesis and evaluating COVID-19 vaccines and therapeutics.","Cell Host Microbe","Sun, Shi-Hui","Chen, Qi","Gu, Hong-Jing","Yang, Guan","Wang, Yan-Xiao","Huang, Xing-Yao","Liu, Su-Su","Zhang, Na-Na","Li, Xiao-Feng","Xiong, Rui","Guo, Yan","Deng, Yong-Qiang","Huang, Wei-Jin","Liu, Quan","Liu, Quan-Ming","Shen, Yue-Lei","Zhou, Yong","Yang, Xiao","Zhao, Tong-Yan","Fan, Chang-Fa","Zhou, Yu-Sen","Qin, Cheng-Feng","Wang, You-Chun","32485164"],"abstract":["Since December 2019, a novel coronavirus SARS-CoV-2 has emerged and rapidly spread throughout the world, resulting in a global public health emergency. The lack of vaccine and antivirals has brought an urgent need for an animal model. Human angiotensin-converting enzyme II (ACE2) has been identified as a functional receptor for SARS-CoV-2. In this study, we generated a mouse model expressing human ACE2 (hACE2) by using CRISPR/Cas9 knockin technology. In comparison with wild-type C57BL/6 mice, both young and aged hACE2 mice sustained high viral loads in lung, trachea, and brain upon intranasal infection. Although fatalities were not observed, interstitial pneumonia and elevated cytokines were seen in SARS-CoV-2 infected-aged hACE2 mice. Interestingly, intragastric inoculation of SARS-CoV-2 was seen to cause productive infection and lead to pulmonary pathological changes in hACE2 mice. Overall, this animal model described here provides a useful tool for studying SARS-CoV-2 transmission and pathogenesis and evaluating COVID-19 vaccines and therapeutics."],"journal":"Cell Host Microbe","authors":["Sun, Shi-Hui","Chen, Qi","Gu, Hong-Jing","Yang, Guan","Wang, Yan-Xiao","Huang, Xing-Yao","Liu, Su-Su","Zhang, Na-Na","Li, Xiao-Feng","Xiong, Rui","Guo, Yan","Deng, Yong-Qiang","Huang, Wei-Jin","Liu, Quan","Liu, Quan-Ming","Shen, Yue-Lei","Zhou, Yong","Yang, Xiao","Zhao, Tong-Yan","Fan, Chang-Fa","Zhou, Yu-Sen","Qin, Cheng-Feng","Wang, You-Chun"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485164","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.chom.2020.05.020","keywords":["sars-cov-2","angiotensin-converting enzyme ii","hace2-ki/nifdc","mouse model","pathogenesis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668704334399930368,"score":180.07407},{"pmid":32378471,"title":"Animal Models for Emerging Coronavirus: Progress and New Insights.","text":["Animal Models for Emerging Coronavirus: Progress and New Insights.","The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (April 17, 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases.","Emerg Microbes Infect","Yuan, Lunzhi","Tang, Qiyi","Cheng, Tong","Xia, Ningshao","32378471"],"abstract":["The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (April 17, 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases."],"journal":"Emerg Microbes Infect","authors":["Yuan, Lunzhi","Tang, Qiyi","Cheng, Tong","Xia, Ningshao"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378471","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/22221751.2020.1764871","keywords":["animal model","coronavirus","infectious disease","respiratory syndrome","vaccine and drug discovery"],"topics":["Treatment"],"weight":1,"_version_":1666597097458106368,"score":169.49089},{"pmid":32380511,"title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.","text":["The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.","Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the corona virus disease 2019 (COVID-19) cases in China and has become a public health emergency of international concern(1). Because angiotensin-converting enzyme 2 (ACE2) is the cell entry receptor of SARS-CoV(5), we used transgenic mice bearing human ACE2 and infected with SARS-CoV-2 to study the pathogenicity of the virus. Weight loss and virus replication in lung were observed in hACE2 mice infected with SARS-CoV-2. The typical histopathology was interstitial pneumonia with infiltration of significant macrophages and lymphocytes into the alveolar interstitium, and accumulation of macrophages in alveolar cavities. Viral antigens were observed in the bronchial epithelial cells, macrophages and alveolar epithelia. The phenomenon was not found in wild-type mice with SARS-CoV-2 infection. Notably, we have confirmed the pathogenicity of SARS-CoV-2 in hACE2 mice. The mouse model with SARS-CoV-2 infection will be valuable for evaluating antiviral therapeutics and vaccines as well as understanding the pathogenesis of COVID-19.","Nature","Bao, Linlin","Deng, Wei","Huang, Baoying","Gao, Hong","Liu, Jiangning","Ren, Lili","Wei, Qiang","Yu, Pin","Xu, Yanfeng","Qi, Feifei","Qu, Yajin","Li, Fengdi","Lv, Qi","Wang, Wenling","Xue, Jing","Gong, Shuran","Liu, Mingya","Wang, Guanpeng","Wang, Shunyi","Song, Zhiqi","Zhao, Linna","Liu, Peipei","Zhao, Li","Ye, Fei","Wang, Huijuan","Zhou, Weimin","Zhu, Na","Zhen, Wei","Yu, Haisheng","Zhang, Xiaojuan","Guo, Li","Chen, Lan","Wang, Conghui","Wang, Ying","Wang, Xinming","Xiao, Yan","Sun, Qiangming","Liu, Hongqi","Zhu, Fanli","Ma, Chunxia","Yan, Lingmei","Yang, Mengli","Han, Jun","Xu, Wenbo","Tan, Wenjie","Peng, Xiaozhong","Jin, Qi","Wu, Guizhen","Qin, Chuan","32380511"],"abstract":["Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the corona virus disease 2019 (COVID-19) cases in China and has become a public health emergency of international concern(1). Because angiotensin-converting enzyme 2 (ACE2) is the cell entry receptor of SARS-CoV(5), we used transgenic mice bearing human ACE2 and infected with SARS-CoV-2 to study the pathogenicity of the virus. Weight loss and virus replication in lung were observed in hACE2 mice infected with SARS-CoV-2. The typical histopathology was interstitial pneumonia with infiltration of significant macrophages and lymphocytes into the alveolar interstitium, and accumulation of macrophages in alveolar cavities. Viral antigens were observed in the bronchial epithelial cells, macrophages and alveolar epithelia. The phenomenon was not found in wild-type mice with SARS-CoV-2 infection. Notably, we have confirmed the pathogenicity of SARS-CoV-2 in hACE2 mice. The mouse model with SARS-CoV-2 infection will be valuable for evaluating antiviral therapeutics and vaccines as well as understanding the pathogenesis of COVID-19."],"journal":"Nature","authors":["Bao, Linlin","Deng, Wei","Huang, Baoying","Gao, Hong","Liu, Jiangning","Ren, Lili","Wei, Qiang","Yu, Pin","Xu, Yanfeng","Qi, Feifei","Qu, Yajin","Li, Fengdi","Lv, Qi","Wang, Wenling","Xue, Jing","Gong, Shuran","Liu, Mingya","Wang, Guanpeng","Wang, Shunyi","Song, Zhiqi","Zhao, Linna","Liu, Peipei","Zhao, Li","Ye, Fei","Wang, Huijuan","Zhou, Weimin","Zhu, Na","Zhen, Wei","Yu, Haisheng","Zhang, Xiaojuan","Guo, Li","Chen, Lan","Wang, Conghui","Wang, Ying","Wang, Xinming","Xiao, Yan","Sun, Qiangming","Liu, Hongqi","Zhu, Fanli","Ma, Chunxia","Yan, Lingmei","Yang, Mengli","Han, Jun","Xu, Wenbo","Tan, Wenjie","Peng, Xiaozhong","Jin, Qi","Wu, Guizhen","Qin, Chuan"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380511","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41586-020-2312-y","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666597097307111424,"score":158.69676},{"pmid":32265331,"pmcid":"PMC7157776","title":"Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.","text":["Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.","Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe and fatal acute respiratory disease in humans and remains endemic in the Middle East since first being identified in 2012. There are currently no approved vaccines or therapies available for MERS-CoV. In this study, we evaluated parainfluenza virus 5 (PIV5)-based vaccine expressing the MERS-CoV envelope spike protein (PIV5/MERS-S) in a human DPP4 knockin C57BL/6 congenic mouse model (hDPP4 KI). Following a single-dose intranasal immunization, PIV5-MERS-S induced neutralizing antibody and robust T cell responses in hDPP4 KI mice. A single intranasal administration of 10(4) PFU PIV5-MERS-S provided complete protection against a lethal challenge with mouse-adapted MERS-CoV (MERSMA6.1.2) and improved virus clearance in the lung. In comparison, single-dose intramuscular immunization with 10(6) PFU UV-inactivated MERSMA6.1.2 mixed with Imject alum provided protection to only 25% of immunized mice. Intriguingly, an influx of eosinophils was observed only in the lungs of mice immunized with inactivated MERS-CoV, suggestive of a hypersensitivity-type response. Overall, our study indicated that PIV5-MERS-S is a promising effective vaccine candidate against MERS-CoV infection.IMPORTANCE MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19.","mBio","Li, Kun","Li, Zhuo","Wohlford-Lenane, Christine","Meyerholz, David K","Channappanavar, Rudragouda","An, Dong","Perlman, Stanley","McCray, Paul B Jr","He, Biao","32265331"],"abstract":["Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe and fatal acute respiratory disease in humans and remains endemic in the Middle East since first being identified in 2012. There are currently no approved vaccines or therapies available for MERS-CoV. In this study, we evaluated parainfluenza virus 5 (PIV5)-based vaccine expressing the MERS-CoV envelope spike protein (PIV5/MERS-S) in a human DPP4 knockin C57BL/6 congenic mouse model (hDPP4 KI). Following a single-dose intranasal immunization, PIV5-MERS-S induced neutralizing antibody and robust T cell responses in hDPP4 KI mice. A single intranasal administration of 10(4) PFU PIV5-MERS-S provided complete protection against a lethal challenge with mouse-adapted MERS-CoV (MERSMA6.1.2) and improved virus clearance in the lung. In comparison, single-dose intramuscular immunization with 10(6) PFU UV-inactivated MERSMA6.1.2 mixed with Imject alum provided protection to only 25% of immunized mice. Intriguingly, an influx of eosinophils was observed only in the lungs of mice immunized with inactivated MERS-CoV, suggestive of a hypersensitivity-type response. Overall, our study indicated that PIV5-MERS-S is a promising effective vaccine candidate against MERS-CoV infection.IMPORTANCE MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19."],"journal":"mBio","authors":["Li, Kun","Li, Zhuo","Wohlford-Lenane, Christine","Meyerholz, David K","Channappanavar, Rudragouda","An, Dong","Perlman, Stanley","McCray, Paul B Jr","He, Biao"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265331","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1128/mBio.00554-20","keywords":["covid-19","mers","coronavirus","vaccine"],"locations":["Imject"],"e_drugs":["aluminum sulfate"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491985068032,"score":151.28262}]}